Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Journal
Age
Showing 1 to 12 of 14783 entries
Sorted by: Best Match Show Resources per page
Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.

Marslew U, Overgaard K, Riis BJ, Christiansen C.
PMID: 1309944
Obstet Gynecol. 1992 Feb;79(2):202-10.

Bone mass, calcium and lipid metabolism, climacteric symptoms, bleeding, blood pressure, and weight changes were studied in 62 healthy postmenopausal women at 3-month intervals throughout 2 years of treatment with continuous estradiol valerate (2 mg) plus cyproterone acetate (1...

Can nandrolone add to the effect of hormonal replacement therapy in postmenopausal osteoporosis?.

Birkenhäger JC, Erdtsieck RJ, Zeelenberg J, van Kuik C, van Veen LC, Birkenhäger-Frenkel DH, Luiken GP, Kooy PP, Gerritsma EJ, Mulder P.
PMID: 1392698
Bone Miner. 1992 Sep;18(3):251-65. doi: 10.1016/0169-6009(92)90811-q.

Thirty-six women with postmenopausal osteoporosis (31 of them with at least one non-traumatic vertebral compression fracture) were matched pair-wise as to age, years since menopause and body mass index and randomized to receive either cyclical estrogen-progestagen replacement treatment (group...

Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis.

Hillard TC, Siddle NC, Whitehead MI, Fraser DI, Pryse-Davies J.
PMID: 1442905
Am J Obstet Gynecol. 1992 Jul;167(1):1-7. doi: 10.1016/s0002-9378(11)91614-7.

OBJECTIVES: This study was designed to assess the incidence of amenorrhea with continuous combined therapy by using two different progestogens and to determine whether early bleeding predicts subsequent bleeding and endometrial response.STUDY DESIGN: Seventy-nine postmenopausal women on sequential estrogen-progestogen...

Tight junctions of human uterine epithelial cells change during the menstrual cycle: a morphometric study.

Murphy CR, Rogers PA, Hosie MJ, Leeton J, Beaton L.
PMID: 1514357
Acta Anat (Basel). 1992;144(1):36-8. doi: 10.1159/000147282.

Tight junctions between luminal epithelial cells of the human uterus were studied by freeze-fracture electron microscopy. It was found that junctional complexity decreased during the menstrual cycle, and we explore how this finding may contribute to the role of...

Ceruloplasmin serum level in post-menopausal women treated with oral estrogens administered at different times.

Clemente C, Russo F, Caruso MG, Giangrande M, Fanizza G, Di Leo A.
PMID: 1318259
Horm Metab Res. 1992 Apr;24(4):191-3. doi: 10.1055/s-2007-1003291.

The liver is an estrogen-responsive organ and the administration of estrogens in humans increases the hepatic synthesis of many proteins. The existence of a circadian rhythm of estrogen receptors in the liver has been proved by different authors. We...

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?.

Owen EJ, Siddle NC, McGarrigle HT, Pugh MA.
PMID: 1327094
Br J Obstet Gynaecol. 1992 Aug;99(8):671-5. doi: 10.1111/j.1471-0528.1992.tb13853.x.

OBJECTIVE: To assess the oestrogen concentrations and symptom relief obtained with 25 mg oestradiol implants.DESIGN: Open, observational study.SUBJECTS: Twelve symptomatic, post-menopausal women seen in a designated menopause clinic.INTERVENTION: A 25 mg oestradiol pellet was inserted subcutaneously, blood samples were...

[Hormone replacement therapy of postmenopausal osteoporosis].

Lin S.
PMID: 1327464
Zhonghua Yi Xue Za Zhi. 1992 May;72(5):313-4.

No abstract available.

Coagulation activation following estrogen administration to postmenopausal women.

Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD.
PMID: 1333098
Thromb Haemost. 1992 Oct 05;68(4):392-5.

We investigated coagulation system activation following estrogen treatment in 29 healthy postmenopausal women. Study participants received conjugated estrogens at 0.625 and 1.25 mg per day, and placebo for 3-month periods in a randomized crossover protocol. Blood samples were obtained...

Current perspective in the management of menopausal and postmenopausal women.

Dumesic DA.
PMID: 1331204
J Clin Pharmacol. 1992 Sep;32(9):774-8. doi: 10.1002/j.1552-4604.1992.tb03883.x.

No abstract available.

Postmenopausal hormone replacement in a perimenopausal woman.

[No authors listed]
PMID: 1354659
Int J Fertil. 1992;37:122-7.

No abstract available.

Oral contraceptive use in osteoporosis.

Khoyi AA, Middleton RK.
PMID: 1421674
Ann Pharmacother. 1992 Sep;26(9):1094-5.

No abstract available.

Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women.

Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R, Sandin K.
PMID: 1508062
Maturitas. 1992 Mar;14(3):225-36. doi: 10.1016/0378-5122(92)90117-m.

The long-term effect on aspects of quality of life (QoL) of treatment with transdermal oestrogen for 2 weeks followed by transdermal oestrogen/progestogen norethisterone acetate/oestradiol TTS 0.25/0.05 mg/day for the next 2 weeks was investigated in postmenopausal women within the...

Showing 1 to 12 of 14783 entries